Lesson of the month 2: Non-uraemic calciphylaxis -an unexpected differential diagnosis for a necrotic ulcer
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A core medical trainee, West Hertfordshire Hospitals international normalised ratio (INR), 2.5), oral hydrocortisone and prophylactic penicillin V for recurrent cellulitis. On admission she was afebrile with stable haemodynamic observations. She had a large tender stellate violaceous lesion with a necrotic centre and surrounding warmth and erythema. The lesion was approximately 3x4 cm in size, situated on the posteromedial aspect of her left thigh (Fig 1) .
Investigations
Admission blood tests revealed raised inflammatory markers (white cell count 11×10 9 /L (reference range 3.6-11.0×10 9 ), C-reactive protein 228 mg/L (reference <5.0 mg/L)), low albumin at 20 g/L (reference range 35-50), normal renal function (urea 2.8 mmol/L, creatinine 41 µmol/L), normal bone profile and parathyroid function (corrected calcium 2.43 mmol/L, phosphate 1.43 mmol/L, parathyroid hormone 3.6 pmol/L), and an INR of 2.8. A creatine kinase level and autoimmune screen were also normal.
Magnetic resonance imaging excluded osteomyelitis. Wound swabs revealed heavy growth of Pseudomonas species and antibiotics were escalated to piperacillin and tazobactam. A biopsy was taken which revealed epidermal necrosis with underlying congestion and inflammation. The small and medium sized vessels showed extensive calcification, consistent with a diagnosis of calciphylaxis (Fig 2) . 
Treatment
Despite treatment the ulcer grew and became more necrotic, and a second ulcer developed on her right thigh. Antibiotic therapy was escalated and a wound care programme was commenced including betamethasone cream and compression bandages. On day 15 of her admission the patient became febrile, tachycardic with atrial fibrillation, and hypotensive. She was admitted to the intensive care unit for further management of septic shock. Her treatment included (i) broad spectrum antibiotics, including daptomycin and gentamicin; (ii) reversal of warfarin with prothrombin complex concentrate and discontinuation of warfarin therapy; (iii) blood transfusion to correct normocytic anaemia; (iv) human albumin solution to correct hypoalbuminaemia; and (v) intravenous infusions of sodium thiosulphate.
Although the patient initially stabilised after 10 days on the intensive care unit, the ulcers became larger, more necrotic and erythematous (Fig 3) . They spread to her buttocks and abdomen. She was deemed not fit for surgical debridement. A decision was made for no further escalation and she was palliated until her death 7 weeks after admission.
Discussion
Calciphylaxis is a highly morbid and often lethal condition which results in cutaneous necrosis. It is characterised by extensive dermal vascular calcification and occlusion with resultant infarction of the skin and subcutis. The pathophysiology of the condition is incompletely understood, however it is a recognised complication of end-stage chronic kidney disease, with a prevalence of up to 4% in haemodialysis patients.
1 Although the disease has been reported in patients with normal renal function (so-called non-uraemic calciphylaxis (NUC)), its incidence is rare. A 2008 systematic review identified just 35 cases, 2 and at least 30 more have since been described.
As a result, although calciphylaxis is more easily suspected in vulnerable patients with end-stage renal failure by nephrologists who are better acquainted with the condition, it poses a significant diagnostic challenge when it occurs in nonuraemic patients. Moreover, the causes of NUC are varied and inconsistent. To date, the two major aetiologies identified are hyperparathyroidism (28%) and malignancy (22%), as well as a number of other unrelated causes (Table 1) . 2 Our patient possessed a number of predisposing risk factors. These included obesity, warfarin therapy, hypoalbuminaemia, systemic corticosteroid use, and being in the at-risk patient demographic (Caucasian middle-aged female).
The association with warfarin therapy is well established. The underlying mechanism is believed to be related to inhibition of vitamin K-dependent carboxylation of an extracellular protein known as matrix G1A protein (MGP). 3 This results in a state of pro-calcification, which is supported by studies in mouse models wherein disruption of MGP leads to extensive vascular calcification. 4 However, warfarin may add diagnostic uncertainty due to confusion with the unrelated phenomenon of warfarin-induced skin necrosis (WISN). Indeed, we initially suspected a possible diagnosis of WISN as a cause of the patient's necrotic ulcers. We note that there have been several case reports of similar initial diagnostic confusion. 5, 6 Both conditions may have similar macroscopic appearances, and similar regions of the skin may be affected, with areas of high adiposity being most at risk. The key difference in presentation is related to the timeline of warfarin therapy. The majority of WISN occurs at the onset of warfarinisation, as early as day 1, peaking at day 3, and rarely occurring beyond day 10. In contrast, warfarin therapy is often long established when it is associated with calciphylaxis. Treatment options for calciphylaxis include management of concurrent infection, treatment of hyperparathyroidism and removal of sensitising factors. There have also been reported cases of successful recovery with intravenous sodium thiosulphate, which is a potent reducing agent and is emerging as an important experimental treatment option. Successful treatment with hyperbaric oxygen has also been reported. Due to the uncertainty of management options however a multi-intervention approach is often adopted. 7, 8 Given the high mortality associated with NUC (reported to be >50%), it is possible that many cases are undiagnosed before death, or misdiagnosed, attributed instead to non-healing leg ulcers of other aetiology. This highlights the importance of raising awareness of the condition, especially given that novel treatment strategies exist for the disease. We encourage general physicians to consider NUC as a differential diagnosis in patients with an established cause or known risk factors. ■ 
